©Reuters. FILE PHOTO: The GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) – GSK beat market estimates for fourth-quarter profit and sales on Wednesday, supported by a strong rollout of its Arexvy respiratory syncytial virus (RSV) vaccine and steady demand for its shingles vaccine and HIV drugs.
According to LSEG data, the British drugmaker posted profit of 28.9 pence per share on revenue of 8.05 billion pounds ($10.20 billion), compared to analysts’ average expectations of 28.63 pence on a turnover of £7.29 billion.
($1 = 0.7892 pounds)